A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of Type-1 diabetes

Drug Delivery

Volumn 23, Issue 8, 2016, Pages 2869-2880

  Mathavan, Sangeetha ^a   Chen Tan, Nigel ^b   Arfuso, Frank ^a   Al Salami, Hani ^a  

^a CURTIN UNIVERSITY   (Australia)

^b CURTIN UNIVERSITY   (Australia)

Author keywords

Microencapsulation; permeation; structure; taurocholic acid; Type 1 diabetes

Indexed keywords

ALGINIC ACID; ALLOXAN; GLICLAZIDE; GLUCOSE; INSULIN; TAUROCHOLIC ACID; ANTIDIABETIC AGENT; BILE ACID; EXCIPIENT; GLUCOSE BLOOD LEVEL; GLUCURONIC ACID; HEXURONIC ACID; MICROCAPSULE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; BIOCOMPATIBILITY; CELL VIABILITY; CONCENTRATION PROCESS; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DESIGN; DRUG EFFECT; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; EX VIVO STUDY; GLUCOSE BLOOD LEVEL; GLUCOSE INTAKE; GLYCEMIC CONTROL; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METABOLIC ACTIVATION; MICROCAPSULE; MICROENCAPSULATION; MUSCLE CELL; NONHUMAN; PH; PRIORITY JOURNAL; RAT; SHEAR RATE; SHEAR STRESS; SINGLE DRUG DOSE; TEMPERATURE; THERMAL ANALYSIS; ANIMAL; CELL SURVIVAL; CHEMISTRY; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DISEASE MODEL; DRUG EFFECTS; DRUG FORMULATION; PARTICLE SIZE; PHARMACOLOGY; PROCEDURES; SOLUBILITY;

ALGINATES; ANIMALS; BILE ACIDS AND SALTS; BLOOD GLUCOSE; CAPSULES; CELL SURVIVAL; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; DRUG COMPOUNDING; EXCIPIENTS; GLICLAZIDE; GLUCURONIC ACID; HEXURONIC ACIDS; HYPOGLYCEMIC AGENTS; PARTICLE SIZE; SOLUBILITY; TAUROCHOLIC ACID;

EID: 84948169831     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2015.1110846     Document Type: Article

References (37)

1. Adeghate E, Schattner P, Dunn E. (2006). An update on the etiology and epidemiology of diabetes mellitus. Ann N Y Acad Sci 1084:1–29
2. Al-Salami H, Butt G, Tucker I, et al. (2009). Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet 34:43–50
3. Al-Salami H, Butt G, Tucker I, et al. (2012). Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet 37:99108
4. Al-Salami H, Butt G, Tucker I, Mikov M. (2008a). Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats. Pharmacol Rep 60:532
5. Al-Salami H, Butt G, Tucker I, Mikov M. (2008b). Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats. Pharmacol Rep 60:532–41
6. Al-Salami H, Butt G, Tucker I, Mikov M. (2008c). Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics. Method Find Exp Clin Pharmacol 30:107–13
7. Al-Salami H, Butt G, Tucker I, Mikov M. (2008d). Probiotic treatment proceeded by a single dose of bile acid and gliclazide exert the most hypoglycemic effect in Type 1 diabetic rats. Med Hypotheses Res 4:93–101
8. Al-Salami H, Butt G, Tucker I, et al. (2008e). Probiotic pre-treatment reduces gliclazide permeation (ex vivo) in healthy rats but increases it in diabetic rats to the level seen in untreated healthy rats. Arch Drug Inf 1:35–41
9. Alam MJ, Rahman MA. (1971). Changes in the saccharoid fraction in rats with alloxan-induced diabetes or injected with epinephrine. Clin Chem 17:915–20
10. Barakat NS, Shazly GA, Almedany AH. (2013). Influence of polymer blends on the characterization of gliclazide–encapsulated into poly (epsilon–caprolactone) microparticles. Drug Dev Ind Pharm 39:352–62
11. Carvalho END, Carvalho NASD, Ferreira LM. (2003). Experimental model of induction of diabetes mellitus in rats. Acta Cirurg Brasil 18:60–4
12. Chan KIA, Elkhider N, Kazarian SG. (2005). Spectroscopic imaging of compacted pharmaceutical tablets. Chem Eng Res Des 83:1303–10
13. Kazarian SG, Chan KLA. (2006). Applications of ATR-FTIR spectroscopic imaging to biomedical samples. Biochim Biophys Acta–Biomembr 1758:858–67
14. Kazarian SG, Kong KWT, Bajomo M, et al. (2005). Spectroscopic imaging applied to drug release. Food Bioprod Process 83:127–35
15. Khatun Z, Nurunnabi M, Reeck GR, et al. (2013). Oral delivery of taurocholic acid linked heparin-docetaxel conjugates for cancer therapy. J Control Release 170:74–82
16. Korec R. (1980). Treatment of alloxan and streptozotocin diabetes in rats by intrafamiliar homo (allo) transplantation of neonatal pancreases. Endocrinol Exp 14:191–8
17. Lankin VZ, Korchin VI, Konovalova GG, et al. (2004). Role of antioxidant enzymes and antioxidant compound probucol in antiradical protection of pancreatic beta-cells during alloxan-induced diabetes. Bull Exp Biol Med 137:20–3
18. Lee E, Kim Y-S, Bae SM, et al. (2009). Polyproline-type helical-structured low-molecular weight heparin (LMWH)–taurocholate conjugate as a new angiogenesis inhibitor. Int J Cancer 124:2755–65
19. Mathews CE, Bagley R, Leiter EH. (2004). ALS/Lt:a new type 2 diabetes mouse model associated with low free radical scavenging potential. Diabetes 53:S125–9
20. Mikov M, Al-Salami H, Golocorbin-Kon S, et al. (2008). The influence of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes. Eur J Drug Metab Pharmacokinet 33:137–42
21. Mooranian A, Negrulj R, Arfuso F, Al-Salami H. (2014a). Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic beta-cells. Artif Cells Nanomed Biotechnol. [Epub ahead of print]. DOI:10.3109/21691401.2014.934457
22. Mooranian A, Negrulj R, Chen-Tan N, et al. (2014b). Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation:a characterization study. Drug Des Dev Ther 8:1003–12
23. Mooranian A, Negrulj R, Chen-Tan N, et al. (2014c). Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol. Drug Des Dev Ther 8:1221
24. Mooranian A, Negrulj R, Chen-Tan N, et al. (2014d). An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer. Drug Des Dev Ther 8:1673–83
25. Mooranian A, Negrulj R, Chen-Tan N, et al. (2014e). An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer. Drug Des Dev Ther 8:1673
26. Mooranian A, Negrulj R, Mathavan S, et al. (2014f). An advanced microencapsulated system:a platform for optimized oral delivery of antidiabetic drug-bile acid formulations. Pharm Dev Technol 20:1–8
27. Mooranian A, Negrulj R, Mathavan S, et al. (2014g). An advanced microencapsulated system:a platform for optimized oral delivery of antidiabetic drug-bile acid formulations. Pharm Dev Technol 20:702–9
28. Phillips P. (2005). Type 2 Diabetes-failure, blame and guilt in the adoption of insulin therapy. Rev Diabet Stud 2:35–9
29. Prajapati VD, Mashru KH, Solanki HK, Jani GK. (2013). Development of modified release gliclazide biological macromolecules using natural biodegradable polymers. Int J Biol Macromol 55:6–14
30. Rakel A, Renier G, Roussin A, et al. (2007). Beneficial effects of gliclazide modified release compared with glibenclamide on endothelial activation and low-grade inflammation in patients with type 2 diabetes. Diabetes Obes Metab 9:127–9
31. Rokstad AMA, Lacík I, De Vos P, Strand BL. (2014). Advances in biocompatibility and physico-chemical characterization of microspheres for cell encapsulation. Adv Drug Deliv Rev 67–68:111–30
32. Sartori C, Finch DS, Ralph B, Gilding K. (1997). Determination of the cation content of alginate thin films by FTIR spectroscopy. Polymer 38:43–51
33. Stetinova V, Kvetina J, Pastera J, et al. (2007). Gliclazide:pharmacokinetic-pharmacodynamic relationships in rats. Biopharm Drug Dispos 28:241–8
34. Tsiani E, Ramlal T, Leiter LA, et al. (1995). Stimulation of glucose uptake and increased plasma membrane content of glucose transporters in L6 skeletal muscle cells by the sulfonylureas gliclazide and glyburide. Endocrinology 136:2505–12
35. Weiss R, Caprio S. (2006). Development of type 2 diabetes in children and adolescents. Minerva Med 97:263–9
36. Xu W, Ling P, Zhang T. (2013). Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs. J Drug Deliv 2013:340315. DOI:10.1155/2013/340315
37. Yang L, Xu Y, Su Y, et al. (2005). FT-IR spectroscopic study on the variations of molecular structures of some carboxyl acids induced by free electron laser. Spectrochim Acta Part A Mol Biomol Spectrosc 62:1209–15